Effect of subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study - PubMed
6 hours ago
- #Quality of Life
- #Post-COVID Treatment
- #Lidocaine-HP-β-CD
- The study assessed subcutaneous lidocaine-HP-β-CD for post-COVID treatment, showing significant improvements in health-related quality of life (SF-12 scores) at 24 and 36 weeks.
- Symptom burden decreased, with 27 out of 30 symptoms improving significantly by week 24, and adverse events were mostly mild injection-site reactions with no serious events reported.
- Researchers noted potential conflicts of interest due to patents related to lidocaine use for post-COVID, held by some authors through Remicine IP BV.